AMGN

AMGEN INC

NasdaqHealthcareBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying$00 buys
Total selling$00 sales
Net open-market$0Buying minus selling
Active insiders4Distinct reporting owners

AMGN transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Ishrak Omar
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SEC filing ↗
$0View disclosure →
Holley Charles M
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SEC filing ↗
$0View disclosure →
Gibbs David W
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Large acquisition
Units acquired were at least 25% of reported post-transaction holdings.
SEC filing ↗
$0View disclosure →
Drake Michael V
Director
DIR
Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
SEC filing ↗
$0View disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Nov 9, 2026

Open-market transaction mix · 0 transactions in the selected period

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026000$0$0$0
Nov 2026004$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Nov 2026 (4)
Oct 2026: 0 insidersNov 2026: 4 insiders
Oct 2026Nov 2026
4distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
4 insiders
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 4 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale—
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
4transactionstxns
  • A · Grants / awards · dominant4 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
Director4

Reported Holdings After

Separated by insider, security, and ownership type

Drake Michael VCommon Stock · Direct
6.03k6.03kNov 6, 2026Nov 6, 2026
6,030.1896Nov 6, 2026
Gibbs David WCommon Stock · Direct
278278Nov 6, 2026Nov 6, 2026
278Nov 6, 2026
Holley Charles MCommon Stock · Direct
13.3k13.3kNov 6, 2026Nov 6, 2026
13,262.066Nov 6, 2026
Ishrak OmarCommon Stock · Direct
7.68k7.68kNov 6, 2026Nov 6, 2026
7,681.9397Nov 6, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
1 active days
Oct 16 → Nov 16
LessMore

AMGEN INC Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at AMGEN INC?

ISHRAK OMAR, HOLLEY CHARLES M, Gibbs David W, Drake Michael V.

When was the latest reported open-market purchase?

No code-P purchase is available for this period.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

No code-P purchases or code-S sales were reported in the selected period.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.